|
drug interaction paxil:
|
drug interaction paxil R: The most commonly observed adverse events associated with the use of PAXIL CR in a pool of 2 trials (incidence of 5.0% or greater and incidence for PAXIL CR at least twice that for placebo drug interaction paxil, derived from Table 1) were: Abnormal ejaculation drug interaction paxil, abnormal vision drug interaction paxil, constipation drug interaction paxil, decreased libido drug interaction paxil, diarrhea drug interaction paxil, dizziness drug interaction paxil, female genital disorders drug interaction paxil, nausea drug interaction paxil, somnolence drug interaction paxil, sweating drug interaction paxil, trauma drug interaction paxil, tremor drug interaction paxil, and yawning. Using the same criteria drug interaction paxil, the adverse events associated with the use of PAXIL CR in a study of elderly patients with major depressive disorder were: Abnormal ejaculation drug interaction paxil, constipation drug interaction paxil, decreased appetite drug interaction paxil, dry mouth drug interaction paxil, impotence drug interaction paxil, infection drug interaction paxil, libido decreased drug interaction paxil, sweating drug interaction paxil, and drug interaction paxil.
drug interaction paxil tremor. Panic Disorder: In the pool of panic disorder studies drug interaction paxil, the adverse events meeting these criteria were: Abnormal ejaculation drug interaction paxil, somnolence drug interaction paxil, impotence drug interaction paxil, libido decreased drug interaction paxil, tremor drug interaction paxil, sweating drug interaction paxil, and female genital disorders (generally anorgasmia or difficulty achieving orgasm). Social Anxiety Disorder: In the social anxiety disorder study drug interaction paxil, the adverse events meeting these criteria were: Nausea drug interaction paxil, asthenia drug interaction paxil, abnormal ejaculation drug interaction paxil, sweating drug interaction paxil, somnolence drug interaction paxil, impotence drug interaction paxil, insomnia drug interaction paxil, and libido decreased. Premenstrual Dysphoric Disorder: The most commonly observed adverse events associated with the use of PAXIL CR either during continuous dosing or luteal phase dosing (incidence of 5% or greater and incidence for PAXIL CR at least twice that for placebo drug interaction paxil, derived from Table 5) were: Nausea drug interaction paxil, asthenia drug interaction paxil, libido decreased drug interaction paxil, somnolence drug interaction paxil, insomnia drug interaction paxil, female genital disorders drug interaction paxil, sweating drug interaction paxil, dizziness drug interaction paxil, diarrhea drug interaction paxil, and constipation. In the luteal phase dosing PMDD trial drug interaction paxil, which employed dosing of 12.5 mg day or 25 mg day of PAXIL CR limited to the 2 weeks prior to the onset of menses over 3 consecutive menstrual cycles drug interaction paxil, adverse events were evaluated during the first 14 days of each off-drug phase. When the 3 off-drug phases were combined drug interaction paxil, the following adverse events were reported at an incidence of 2% or greater for PAXIL CR and were at least twice t.
drug interaction paxil Ce of 5% or greater and incidence for PAXIL CR at least twice that for placebo drug interaction paxil, derived from Table 5) were: Nausea drug interaction paxil, asthenia drug interaction paxil, libido decreased drug interaction paxil, somnolence drug interaction paxil, insomnia drug interaction paxil, female genital disorders drug interaction paxil, sweating drug interaction paxil, dizziness drug interaction paxil, diarrhea drug interaction paxil, and constipation. In the luteal phase dosing PMDD trial drug interaction paxil, which employed dosing of 12.5 mg day or 25 mg day of PAXIL CR limited to the 2 weeks prior to the onset of menses over 3 consecutive menstrual cycles drug interaction paxil, adverse events were evaluated during the first 14 days of each off-drug phase. When the 3 off-drug phases were combined drug interaction paxil, the following adverse events were reported at an incidence of 2% or greater for PAXIL CR and were at least twice th.
drug interaction paxil 
drug interaction paxil | | | | | |
drug interaction paxil
|
|
Xa , fluoxetine e.g., Prozac , fluvoxamine e.g., Luvox , sertraline Zoloft ) or Street drugs (LSD, MDMA e.g., ecstasy , marijuana) or Sumatriptan (e.g., Imitrex) or Tramadol (e.g., Ultram) or Trazodone (e.g., Desyrel) or Tryptophan or Venlafaxine (e.g., Effexor)-Using these medicines with paroxetine may increase the chance of developing a rare, but very serious, unwanted effect known as the serotonin syndrome. This syndrome may cause confusion, diarrhea, fever, poor coordination, restlessness, shivering, sweating, talking or acting with excitement you cannot control, trembling or shaking, or twitching. If you develop these symptoms, contact your doctor as soon as possible. Moclobemide (e.g., Manerix)-The risk of developing serious unwanted effects, including the serotonin syndrome, is increased. Use of moclobemide with paroxetine is not recommended. Also, it is recommended that 3 to 7 days be allowed between stopping treatment with moclobemide and starting treatment with paroxetine, and that 2 weeks be allowed between stopping treatment with paroxetine and starting treatment with moclobemide. Monoamine oxidase (MAO) inhibitor activity (isocarboxazid e.g., Marplan , phenelzine e.g., Nardil , procarbazine e.g., Matulane , selegiline e.g., Eldepryl , tranylcypromine e.g., Parnate )-Do not take paroxetine while you are taking or within 2 weeks of taking an MAO inhibitor , or you may develop confusion, agitation, restlessness, stomach or intestinal symptoms, sudden high body temperature, extremely high blood pressure, severe convulsions, or the serotonin syndrome. At least 14 da
|
|
